Full-Time

Portfolio and Program Management Senior Director

Biotech Unit

Posted on 5/9/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$214.5k - $284.5k/yr

+ Annual Bonus + Incentive Compensation + Equity Awards

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
Risk Management
Requirements
  • Solid knowledge and expertise of managing scaled and complex global portfolio and programs
  • Good understanding of worldwide clinical trial expertise and best practices
  • Excellent interpersonal skills and the ability to build and maintain positive work relationships to effectively interface at all levels across the organization
  • PMP certification a plus
  • Experience in Oncology/Hematology drug development is preferred
  • Fluent in written and verbal English. Desirable: knowledge of Mandarin
  • Proven ability to make sound judgement and decisions. Possess the ability to quickly assess problems/situations and provide effective resolution/solution
  • Detail-oriented without losing sight of the big picture
  • Have the ambition and passion to drive value and impact with a “can-do” attitude, willing to take calculated risk
  • Adopt an open and creative mindset to pilot new concepts and overcome challenges
  • High learning agility
  • Drive strategic PPM within Biotech Unit; integrate business case, mitigate risks and manage resources
  • Make operation-level decisions under set thresholds
  • Accountable for decisions even facing uncertainties and for implementation of development strategy
  • In-depth pharmaceutical industrial and clinical knowledge and expertise to drive operational excellence
  • Sufficient experience and ability to work in an environment that requires seamless cross-function collaboration and handling complexity
  • Proven ability to effectively work in a cross-region, cross-function matrix; able to work effectively in diverse cultures, showing aptitude in modifying style
  • Business acumen - understand unmet market needs; provide clear path to win; demonstrated track record in driving innovation through to the global commercialization of assets
  • Strategic and Decisive Leader - leadership skills that demonstrate energy, passion, courage, vision and demonstrated competence in thinking strategically, analytically, and innovatively; able to analyze and provide solutions to complex challenges; proven experience as a successful decisive leader in a strategic multifunctional environment quickly and creatively
  • Able to effectively communicate at multiple levels of the organization
  • Strong change management experience and experience with building new teams preferred
  • Master’s degree (PhD preferred) with 8+ years’ experience in drug development or commercially within academia, consulting, pharmaceutical or biotechnology industry
  • 5+ years in leadership roles as leader in a multicultural & international (global) portfolio environment a plus
  • Experience of working with cross functional teams required
Responsibilities
  • Develop, validate, and maintain project plans, schedules, and lead team planning session including develop team charter, define project scope, and ensure global cross-functional alignment
  • Support Head of Biotech Unit on developing goals and operational KPIs
  • Plan, track, and manage project milestones, goals, KPIs, project budget, dependencies, and critical path
  • Implement good project and risk management practices
  • Liaise with internal and external collaborators to deliver high quality work product, presentations, etc.
  • Lead process improvement initiatives, e.g., headcount and budget planning, budget change control, program management dashboards and reports, risk management, etc., and continuous identify any opportunities for improvement
  • Assume the responsibilities and leadership of independently providing alliance management for drug development partners and assure smooth external collaboration
  • Consult with Advisory Committee for relevant topics and incorporate the ideas into strategy and execution if appropriate
  • Track project status, goals, operational KPIs, and enforce quality KPIs
  • Ensure appropriate systems and technologies deployed in Biotech Unit and well interfaced with Global R&D
  • Champions a global mindset and approach to foster collaboration and consistency across the organization
  • Organize and coordinate core team meetings and facilitate the meetings to drive efficient discussion, alignment and decision making
  • Understand competitors’ movements and market intelligence and be able to translate the insight and acumen into developing strategies
  • Participate company-wise standard discussion, finalization, and implementation
  • Manage the governance process for BTU
  • Other duties as assigned
Desired Qualifications
  • PMP certification a plus
  • Experience in Oncology/Hematology drug development is preferred
  • Desirable: knowledge of Mandarin
  • Strong change management experience and experience with building new teams preferred
  • Global Competencies - Fosters Teamwork

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...